NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript [Seeking Alpha]
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: Seeking Alpha
Company Participants Xi-Yong Fu - CEO & Director Emmett Cunningham - Co-Founder & Executive Chairman Cadmus Rich - Chief Medical Officer Carlos Quezada-Ruiz Nikolas JS London Emmett T. Cunningham Conference Call Participants Christopher Liu - Lucid Capital Markets, LLC, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to the NovaBridge Biosciences Business Update Call. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be made available on the NovaBridge website following the conclusion of the event. I'd now like to turn the call over to Xi-Yong Fu, Chief Executive Officer at NovaBridge Biosciences. Please go ahead, Xi-Yong Fu. Xi-Yong Fu CEO & Director Thanks, Tara. Good morning, everyone. I'm Xi-Yong Fu, CEO of NovaBridge. Once again, welcome to VIS-101 clinical data
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]Yahoo! Finance
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerGlobeNewswire
- Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyPR Newswire
- NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study [Yahoo! Finance]Yahoo! Finance
NBP
Sec Filings
- 3/16/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/3/26 - Form 6-K
- NBP's page on the SEC website